Menu

NIH’s Neuroscience Institute Plans to Limit Financial Support for Well-Funded Investigators

Under a new policy, the National Institute of Neurological Disorders and Stroke will provide fewer grants to labs receiving more than $1 million in funds.

May 3, 2018
Diana Kwon

NCI, CHRIS SPIELMANN

The National Institute of Neurological Disorders and Stroke (NINDS), which is part of the National Institutes of Health (NIH), will limit the number of grants it provides to well-funded investigators, according to a new policy it announced last week (April 27).

In 2012, the NIH implemented an institutes-wide policy under which grant applications from investigators already receiving more than $1 million in funding would receive additional scrutiny. The new NINDS rules, which will apply to grants under consideration from January 2019 and beyond, will extend the stricter review to labs whose funding support would exceed $1 million after the acceptance of a pending proposal.

The policy “will allow us to fund more early stage investigators and help people who just missed the pay line [funding cutoff] and are about to drop off the radar screen,” Robert Finkelstein, the extramural research director at NINDS, tells Science.

See “Proposed NIH Grant Cap Criticized

Last year, the NIH proposed a grant cap, based on its funding metric called the Grant Support Index (GSI), for investigators who received more than three R01 grants, in order to provide more funding opportunities for early-career researchers. However, after drawing heavy criticism from the research community, the NIH decided to abandon that plan and instead created the Next Generation Researchers Initiative, a special fund for early- to mid-career investigators.

“When the GSI went away the problem of funding more investigators didn’t disappear. So something has to be done to fund more people,” Howard Garrison, director of public affairs at the Federation of American Societies for Experimental Biology, tells Science.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Norgen Biotek Achieves Illumina Propel Certification as a Service Provider for Next Generation Sequencing

Norgen Biotek Achieves Illumina Propel Certification as a Service Provider for Next Generation Sequencing

Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on nucleic acid and protein stabilization and purification, as well as providing high quality services to the scientific community, today announced that it has become Propel-Certified through Illumina as a Next Generation Sequencing (NGS) service provider.

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.